nach oben

International Journal of Public Health

Erschienen in:

22.04.2016 | Original Article

Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel

verfasst von: Gary M. Ginsberg, Colin Block, Chen Stein-Zamir

Erschienen in: International Journal of Public Health | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Using cost-utility analysis, to evaluate whether or not to adopt a Neisseria meningitidis serogroup B vaccination programme for Israeli children.

Methods

Epidemiological, demographic, health service utilisation and economic data were integrated into a spreadsheet model to calculate the cost per averted disability-adjusted life year (DALY) of the intervention.

Results

Assuming 78 % vaccine efficacy with no herd immunity, vaccination will prevent 223 cases and 22 deaths over a 100-year period. Based on vaccine price of $60 per dose, total intervention costs ($315,400,000) are partially offset by a $22,700,000 reduction in treatment and sequelae costs as a result of decreased morbidity. The intervention was not cost-effective since the net cost ($292,700,000) per averted DALY gained (1249 mostly due to decreased mortality) was $234,394. Additional two dose catch-up programmes vaccinating children in cohorts aged 1–2 to 1–13 were also not cost-effective.

Conclusions

The vaccination will become cost-effective if vaccine costs fall below $19.44 per dose. However, in identified high risk areas, the vaccine would be cost-effective and could be recommended for use both with and without catch-up campaigns.

Nur mit Berechtigung zugänglich

Arnold R, Galloway Y, McNicholas A, O’Hallahan J (2011) Effectiveness of a vaccination program for an epidemic of meningococcal B in New Zealand. Vaccine 29:7100–7106CrossRefPubMed

Ben-Shimol S, Dagan R, Schonmann Y et al (2012) Dynamics of childhood invasive meningococcal disease in Israel during a 22-year period (1989–2010). Infection 41:791–798. doi:10.1007/s15010-013-0439-6 CrossRef

Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R, For the members of the Canadian immunization Monitoring Program Active (IMPACT) (2013) The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J 32:e20–e25. doi:10.1097/INF.0b013e3182706b89 CrossRefPubMed

Brouwer MC, McIntyre P, Prasad K, van de Beek D (2013) Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 6:CD004405. doi:10.1002/14651858.CD004405.pub4. Accessed 21 Jan 2015

Buysse CMP, Raat H, Hazelet JA et al (2008) Long-term health status in childhood survivors of meningococcal septic shock. Arch Pediatr Adolesc Med 162:1036–1041CrossRefPubMed

Buysse CM, Oranje AP, Zuidema E, Hazalet JA, Hop WCJ, Diepstaten AF, Joosten KFM (2009) Long-term skin scarring and orthopaedic sequelae in survivors of meningococcal septic shock. Arch Dis Child 94:381–386CrossRefPubMed

Buysse CMP, Vermunt LCAC, Raat H, Hazalet JA, Hop WCJ, Utens EMWJ, Joosten KFM (2010) Surviving meningococcal septic shock in childhood: long-term overall outcome and the effect of health-related quality of life. Crit Care 14:R124. doi:10.1186/cc9087 (Published Online 29 June 2010)

Central Bureau of Statistics (2015) Annual Statistical Abstract 2015. CBS, Jerusalem

Centres for Disease Control and Prevention (2005) Prevention and control of meningococcal disease recommendations of the advisory committee on immunization practices (ACIP). MMWR 54:1–21

Chandran A, Herbert H, Misurski D, Santashan M (2011) Long-term sequelae of childhood bacterial meningitis. Pediatr Infect Dis J 30:3–6CrossRefPubMed

Christensen H, May M, Bowen L, Hickman M, Trotter CL (2010) Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 10:853–861CrossRefPubMed

Christensen H, Hickman M, Edmunds WJ, Trotter CL (2013) Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine 31:2638–2646CrossRefPubMedPubMedCentral

Christensen H, Trotter CL, Hickman M, Edmunds WJ (2014) Re-evaluating cost effectiveness of universal meningitis vaccination (Bexero) in England: modelling study. BMJ 349:g5725CrossRefPubMedPubMedCentral

De Wals P, Deceuninck G, Lefebvre B, Boulianne N, De Serres G (2011) Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada. Pediatr Infect Dis J 30(7):566–569. doi:10.1097/INF.0b013e31820e8638 CrossRefPubMed

Delbos V, Lemée L, Bénichou J et al (2013) Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage. Vaccine 31:4416–4420CrossRefPubMed

Dellicour S, Greenwood B (2007) Systematic review: impact of meningococcal vaccination on pharyngeal carriage of meningococci. Trop Med Int Health 12:1409–1421CrossRefPubMed

Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I (2010) Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 10:317–332CrossRefPubMed

Edwards MS, Baker CJ (1981) Complications and sequelae of meningococcal infections in children. J Pediat 99(4):540–545CrossRefPubMed

Erickson L, De Wals P (1998) Complications and sequelae of meningococcal disease in Quebec, Canada, 1990–1994. Clin Infect Dis 26:1159–1164CrossRefPubMed

FDA News Release (2014) First vaccine approved by FDA to prevent serogroup B Meningococcal disease. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm420998.html. Accessed 1 Jan 2015

Frosi G, Biolchi A, Sapio ML et al (2013) Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 31:4968–4974CrossRefPubMed

Gill C (2013) Novel assessment of a novel meningitis B vaccine. Lancet Infect Dis 5:381–382. doi:10.1016/S1473-3099(13)70037-9 (Epub 2013 Feb 13) CrossRef

Ginsberg GM, Kark J, Einav S (2015) Cost utility analysis of cardiac resuscitation services in Jerusalem. Resuscitation 86:54–61CrossRefPubMed

Gorringe AR, Pajon R (2012) Bexsero: a multicomponent vaccine for prevention of meningococcal disease. Hum Vaccines Immunother 8:174–183CrossRef

Gossger N, Snape MD, Yu LM, European MenB Vaccine Study Group et al (2012) Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 307(6):573–582CrossRefPubMed

Hakin B, Cosford P (2015) Introduction of Men B immunisation for infants. Public Health England, NHS Gateway Number: 03517. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/437906/150622_MenB_bipartite_letter.pdf

Healy CM, Butler KM, Smith EO et al (2002) Influence of serogroup on the presentation, course, and outcome of invasive meningococcal disease in children in the Republic of Ireland, 1995–2000. Clin Infect Dis 34:1323–1330CrossRefPubMed

Holst J, Feiring B, Fuglesang JE, Høiby EA, Nøkleby H, Aaberge IS, Rosenqvist E (2003) Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitis serogroup B disease. Vaccine 21:734–737CrossRefPubMed

Huels J, Wassil J, Bonefeld L, Watson P (2013) Sensitivity analysis of a model used to predict the cost effectiveness of bexero for immunisation against meningococcal disease in the United Kingdom. In: Poster presented at meningitis and septacemia in children and adults, 5–6 November 2013, London

Israel Center for Disease Control (2012) Notifiable infectious diseases in Israel, 60 years of surveillance 1951–2010. Publication No. 342

Izuierdo G, Torres JP, Santolya ME, Valenzuela MT, Vega J, Chomali M (2015) Cost-effectiveness analysis of a multicomponent meningococcal serogroup B (4CMeb B) vaccine in epidemic situation in a middle-income country. Hum Vaccine Immunother 11:875–883. doi:10.1080/21645515.2015.1010885 CrossRef

Jacobs P, Noseworthy TW (1990) National estimates of intensive care utilization and costs. Crit Care Med 18:1282–1286CrossRefPubMed

JCVI (2014) JCVI position statement on use of bexsero meningococcal B vaccine in the UK. 2014. https://www.gov.uk/government/publications/meningococcal-b-vaccine-jcvi-position-statement. Accessed 21 Aug 2014

Lozano R, Naghavi M, Foreman K et al (2012) Global and regional mortality from 235 Causes of Death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095–2128CrossRefPubMed

McNicholas A, Galloway Y, Stehr-Green P et al (2007) Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004–2006. Hum Vaccines 3:196–204CrossRef

Meningococcal B Pilot Project Task Group (2014). The recommended use of the multicomponent meningococcal B (4CMENB) vaccine in Canada: common guidance statement. Ottawa

Ministry of Health (2012) Ambulatory and hospitalization price data July 1st 2012. http://www.health.gov.il/subjects/finance/taarifon/pages/pricelist.aspx. Accessed 11 July 2013

Novartis Media release (2012) Novartis receives positive CHMP opinion for Bexsero^®, a groundbreaking vaccine to help prevent devastating MenB infections, the leading cause of meningitis in Europe. http://www.novartis.com/newsroom/media-releases/en/2012/1658747.shtml. Accessed 15 May 2013

Pouwels KB, Hak E, van der Ende A, Christenden H, van der Dobbelstein GP, Postma MJ (2013) Cost-effectiveness of vaccination against meningococcal B among Dutch infants. Hum Vaccines Immunother 9:1–10CrossRef

Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E (2003) Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 326:365–366CrossRefPubMedPubMedCentral

Read RC, Baxter D, Chadwick DRI et al (2014) Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 384:2123–2131CrossRefPubMed

Scholten RJ, Bijlmer HA, Valkenburg HA, Dankert J (1994) Patient and strain characteristics in relation to the outcome of meningococcal disease: a multivariate analysis. Epidemiol Infect 112:115–124CrossRefPubMedPubMedCentral

Scott RD, Meltzer MI, Erikson LJ, DeWals P, Rosenstein NE (2002) Vaccinating first-year college students living in dormitories for meningococcal disease. Am J Prev Med 23:98–105CrossRefPubMed

Slack R, Hawkins KC, Gilhooley L, Addison GM, Lewis MA, Webb NJA (2005) Long-term outcome of meningococcal sepsis-associated acute renal failure. Pediatr Crit Care Med 6:477–479CrossRefPubMed

Sridhar S, Greenwood B, Head C et al (2015) Global incidence of serogroup B invasive meningococcal disease: a systematic review. Lancet Infect Dis 15:1334–1346. doi:10.1016/S1473-3099(15)00217-0 (Epub 2015 Oct 6) CrossRefPubMed

Stein-Zamir C, Abramson N, Zentner G, Sloob H, Valinsky L, Block C (2008) Invasive meningococcal disease in children in Jerusalem. Epidemiol Infect 136:82–89

Stein-Zamir C, Shoob H, Sokolov I, Kunbar A, Abramson N, Zimmerman D (2014) The clinical features and long-term sequelae of invasive meningococcal disease in children. Pediatr Infect Dis J 33:777–779CrossRefPubMed

Tirani M, Meregaglia M, Melegaro A (2015) Health and economic outcomes of introducing the new Men B vaccine (bexero) into the Italian routine infant immunisation programme. PLoS One 10:e0123383. doi:10.1371/journal.pone.0123383 CrossRefPubMedPubMedCentral

Trotter CL, Edmunds WJ (2006) Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model. Med Decis Mak 26:38–47CrossRef

Trotter CL, Andrews NJ, Zaczmarski EB, Miller E, Ramsay ME (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364:365–367CrossRefPubMed

Tu HA, Deeks SL, Morris SK et al (2014) Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada. Vaccine 32:5436–5446CrossRefPubMed

Vesikari T, Eposito S, Ypma E et al (2013) Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMEN B) administered concomitantly with routine infant and child vaccinations: results of two randomized trials. Lancet 381:825–35 (Erratum in: Lancet (2013) 381: 804)

Viner RE, Booy R, Johnson H et al (2012) Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol 11:774–783CrossRefPubMed

WHO Commission on MacroEconomics and Health (2001) Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. World Health Organization, Geneva, p 2001

Wise J (2014) News: meningitis B vaccine to be introduced in UK after U turn on its cost effectiveness. BMJ 348:g2327. doi:10.1136/bmj.g2327 CrossRefPubMed

World Health Organization (1996) Murray CJL, Lopez AD (eds) The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. WHO, USA

Wright C, Wordsworth R, Glennie L (2013) Counting the cost of meningococcal disease: scenarios of severe meningitis and septicemia. Paediatr Drugs 15:49–58CrossRefPubMed

Titel: Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel
verfasst von: Gary M. Ginsberg
Colin Block
Chen Stein-Zamir
Publikationsdatum: 22.04.2016
Verlag: Springer International Publishing
Erschienen in: International Journal of Public Health / Ausgabe 6/2016
Print ISSN: 1661-8556
Elektronische ISSN: 1661-8564
DOI: https://doi.org/10.1007/s00038-016-0821-0

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Predictors of nicotine withdrawal symptoms: findings from the first randomized smoking cessation trial in a low-income country setting

Caste-ethnic disparity in vaccine use among 0- to 5-year-old children in Nepal: a decomposition analysis

Stunting and weight statuses of adolescents differ between public and private schools in urban Gambia

Utilization of health-care services among immigrants recruited through non-profit organizations in southern Italy

Effectiveness of health warnings for waterpipe tobacco smoking among college students

Fifty years of serving public health: the Association of Schools of Public Health in the European Region moving forward to the next half-century